Cargando…
小细胞肺癌免疫治疗研究进展
Small cell lung cancer (SCLC) is complex heterogeneous due to unclear biological characteristics in terms of cell origin, pathogenesis and driver genes etc. Diagnosis and treatment of SCLC has been slowly improved and few breakthroughs have been discovered up to now. Therefore new strategies are urg...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000108/ https://www.ncbi.nlm.nih.gov/pubmed/24949688 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.06.07 |
_version_ | 1783331621149081600 |
---|---|
collection | PubMed |
description | Small cell lung cancer (SCLC) is complex heterogeneous due to unclear biological characteristics in terms of cell origin, pathogenesis and driver genes etc. Diagnosis and treatment of SCLC has been slowly improved and few breakthroughs have been discovered up to now. Therefore new strategies are urgently needed to improve the efficacy of SCLC treatment. Tumor immunotherapy has potential to restore and trigger the immune system to recognize and eliminate tumor cells, notably it has only minimal adverse impact on normal tissue. Cancer vaccine, adoptive immunotherapy, cytokines and checkpoint inhibitors have now been launched for clinical treatment of SCLC. Ipilimumab is the most promising medicine of immunotherapy. Immunotherapy is expected to bring new vision to the treatment of SCLC. And further researches are needed on such problems affecting efficacy of immunotherapy as the heterogeneity of SCLC, the uncertainty of target for immunotherapy, the immune tolerance, etc. |
format | Online Article Text |
id | pubmed-6000108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60001082018-07-06 小细胞肺癌免疫治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is complex heterogeneous due to unclear biological characteristics in terms of cell origin, pathogenesis and driver genes etc. Diagnosis and treatment of SCLC has been slowly improved and few breakthroughs have been discovered up to now. Therefore new strategies are urgently needed to improve the efficacy of SCLC treatment. Tumor immunotherapy has potential to restore and trigger the immune system to recognize and eliminate tumor cells, notably it has only minimal adverse impact on normal tissue. Cancer vaccine, adoptive immunotherapy, cytokines and checkpoint inhibitors have now been launched for clinical treatment of SCLC. Ipilimumab is the most promising medicine of immunotherapy. Immunotherapy is expected to bring new vision to the treatment of SCLC. And further researches are needed on such problems affecting efficacy of immunotherapy as the heterogeneity of SCLC, the uncertainty of target for immunotherapy, the immune tolerance, etc. 中国肺癌杂志编辑部 2014-06-20 /pmc/articles/PMC6000108/ /pubmed/24949688 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.06.07 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 小细胞肺癌免疫治疗研究进展 |
title | 小细胞肺癌免疫治疗研究进展 |
title_full | 小细胞肺癌免疫治疗研究进展 |
title_fullStr | 小细胞肺癌免疫治疗研究进展 |
title_full_unstemmed | 小细胞肺癌免疫治疗研究进展 |
title_short | 小细胞肺癌免疫治疗研究进展 |
title_sort | 小细胞肺癌免疫治疗研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000108/ https://www.ncbi.nlm.nih.gov/pubmed/24949688 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.06.07 |
work_keys_str_mv | AT xiǎoxìbāofèiáimiǎnyìzhìliáoyánjiūjìnzhǎn AT xiǎoxìbāofèiáimiǎnyìzhìliáoyánjiūjìnzhǎn AT xiǎoxìbāofèiáimiǎnyìzhìliáoyánjiūjìnzhǎn AT xiǎoxìbāofèiáimiǎnyìzhìliáoyánjiūjìnzhǎn |